WO2002011674A3 - Method and reagent for the inhibition of calcium activated chloride channel-1 (clca-1) - Google Patents
Method and reagent for the inhibition of calcium activated chloride channel-1 (clca-1) Download PDFInfo
- Publication number
- WO2002011674A3 WO2002011674A3 PCT/US2001/024970 US0124970W WO0211674A3 WO 2002011674 A3 WO2002011674 A3 WO 2002011674A3 US 0124970 W US0124970 W US 0124970W WO 0211674 A3 WO0211674 A3 WO 0211674A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chloride channel
- clca
- inhibition
- reagent
- calcium activated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001283222A AU2001283222A1 (en) | 2000-08-09 | 2001-08-09 | Method and reagent for the inhibition of calcium activated chloride channel-1 (clca-1) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22438300P | 2000-08-09 | 2000-08-09 | |
US60/224,383 | 2000-08-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002011674A2 WO2002011674A2 (en) | 2002-02-14 |
WO2002011674A3 true WO2002011674A3 (en) | 2003-09-25 |
Family
ID=22840434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/024970 WO2002011674A2 (en) | 2000-08-09 | 2001-08-09 | Method and reagent for the inhibition of calcium activated chloride channel-1 (clca-1) |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001283222A1 (en) |
WO (1) | WO2002011674A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1390255A (en) * | 1999-11-24 | 2003-01-08 | 武田药品工业株式会社 | Use of disease-associated gene |
BRPI0410706A (en) * | 2003-05-28 | 2006-06-13 | Wyeth Corp | soluble clca-1 and clca-1 antagonists |
EP3263115A1 (en) * | 2016-06-30 | 2018-01-03 | Technische Hochschule Mittelhessen | Invention relating to an agent combating pseudomonas aeruginosa |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995011304A1 (en) * | 1993-10-18 | 1995-04-27 | Ribozyme Pharmaceuticals, Inc. | Catalytic dna |
WO1997026270A2 (en) * | 1996-01-16 | 1997-07-24 | Ribozyme Pharmaceuticals, Inc. | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules |
WO1998032846A2 (en) * | 1997-01-23 | 1998-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acid treatment of diseases or conditions related to levels of c-fos |
WO1999055857A2 (en) * | 1998-04-29 | 1999-11-04 | Ribozyme Pharmaceuticals, Inc. | Nucleoside triphosphates and their incorporation into ribozymes |
-
2001
- 2001-08-09 WO PCT/US2001/024970 patent/WO2002011674A2/en active Application Filing
- 2001-08-09 AU AU2001283222A patent/AU2001283222A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995011304A1 (en) * | 1993-10-18 | 1995-04-27 | Ribozyme Pharmaceuticals, Inc. | Catalytic dna |
WO1997026270A2 (en) * | 1996-01-16 | 1997-07-24 | Ribozyme Pharmaceuticals, Inc. | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules |
WO1998032846A2 (en) * | 1997-01-23 | 1998-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acid treatment of diseases or conditions related to levels of c-fos |
WO1999055857A2 (en) * | 1998-04-29 | 1999-11-04 | Ribozyme Pharmaceuticals, Inc. | Nucleoside triphosphates and their incorporation into ribozymes |
Non-Patent Citations (5)
Title |
---|
COUTURE L A ET AL: "Anti-gene therapy: the use of ribozymes to inhibit gene function", TRENDS IN GENETICS, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 12, no. 12, 1 December 1996 (1996-12-01), pages 509, XP004071051, ISSN: 0168-9525 * |
DATABASE GENBANK [online] 14 December 1998 (1998-12-14), "Homo sapiens calcium-dependent chloride channel-1 (hCLCA1) mRNA, complete cds", XP002219572, Database accession no. AF039400 * |
GRUBER A D ET AL: "GENOMIC CLONING, MOLECULAR CHARACTERIZATION, AND FUNCTIONAL ANALYSIS OF HUMAN CLCA1, THE FIRST HUMAN MEMBER OF THE FAMILY OF CA2+-ACTIVATED CI CHANNEL PROTEINS", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 54, 1998, pages 200 - 214, XP002945247, ISSN: 0888-7543 * |
LUDWIG J ET AL: "Extending the cleavage rules for the hammerhead ribozyme: mutating adenosine15.1 to inosine15.1 changes the cleavage site specificity from N16.2U16.1H17 to N16.2C16.1H17", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 26, no. 10, 15 May 1998 (1998-05-15), pages 2279 - 2285, XP002084035, ISSN: 0305-1048 * |
VAISH ET AL: "In vitro selection of a purine nucleotide-specific hammerhead-like ribozyme", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 95, no. 5, 1 March 1998 (1998-03-01), pages 2158 - 2162, XP002097465, ISSN: 0027-8424 * |
Also Published As
Publication number | Publication date |
---|---|
WO2002011674A2 (en) | 2002-02-14 |
AU2001283222A1 (en) | 2002-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003074550A3 (en) | Pin1-modulating compounds and methods of use thereof | |
EP1263765A4 (en) | ALTERATION OF CELLULAR BEHAVIOR BY ANTISENSE MODULATION OF mRNA PROCESSING | |
WO1999046372A3 (en) | Ribozymes capable of inhibiting the expression of the ccr5 receptor | |
GB0404561D0 (en) | Active controlled bottomhole pressure system & method background of the invention | |
MXPA03002562A (en) | Method and system for providing settlement of interconnected packet-switched networks. | |
WO2002030353A3 (en) | NF-λB INHIBITORS | |
WO2002036743A3 (en) | Antisense modulation of calreticulin expression | |
WO2002072736A3 (en) | Demulsification of water-in-oil emulsions | |
AU2002365166A1 (en) | Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis | |
AU2002227442A1 (en) | Method for the prevention, inhibition, or treatment of vaginitis and/or bacterial vaginosis using polystyrene sulfonate | |
WO2002026968A3 (en) | Antisense iap nucleic acids and uses thereof | |
EG23184A (en) | Targeting system and method of targeting. | |
WO2001057206A3 (en) | Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme | |
WO2005007123A3 (en) | Pin1-modulating compounds and methods of use thereof | |
MXPA03001717A (en) | Method for treatment of migraine. | |
WO2001088124A3 (en) | Method and reagent for the inhibition of erg | |
ZA200306124B (en) | Method of treating of demyelinating diseases or conditions. | |
MXPA02012907A (en) | Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity. | |
WO2002018590A3 (en) | Identification of activated receptors and ion channels | |
WO2003057843A8 (en) | Methods and materials for modulating trpc4 | |
WO2002011674A3 (en) | Method and reagent for the inhibition of calcium activated chloride channel-1 (clca-1) | |
WO2003070169A3 (en) | Aminodiphosphonate apolipoprotein e modulators | |
WO2003057847A8 (en) | METHODS AND MATERIALS FOR MODULATING ENaC-BETA | |
AU2001243297A1 (en) | Method for treating or preventing depression | |
WO2002091926A3 (en) | Inhibitors of dna methyltransferase isoforms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |